Health & Environmental Research Online (HERO)


Print Feedback Export to File
2251585 
Technical Report 
Clinical evaluation of perhexiline maleate in the treatment of patients with chronic coronary insufficiency 
Masoni, A; Tomasi, AM; Oriani, GA 
1975 
IPA/77/238024 
Heart J 
REF 44 
145-152 
eng 
IPA COPYRIGHT: ASHP A long term open trial test was carried out in 13 patients to evaluate the effects of perhexiline (I) in the treatment of coronary artery disease, namely angina pectoris. In all patients, the starting dose was 400 mg/day. This dosage was modified in 4 patients. During the treatment period, all other antianginal drugs were discontinued except nitroglycerin (II). Eleven subjects remained evaluable. In these patients, the average basal value of angina attacks/week was 16.7; the reduction of crises with I treatment exceeded 60% at the first control visit and 98% at the sixth checkup. These reductions were statistically significant. Results at the sixth checkup were maintained throughout the remaining treatment period. The mean basal value of II tablets/week was 15.7. At first control visit a reduction of 72.9% in consumption was seen. II consumption had practically ceased at the sixth checkup (reduction of up to 98.8%). No important changes were recorded in pulse rate at rest, blood pressure, respiration or body temperature. Tests of hematological and renal function remained normal. In conclusion, results were encouraging, however, larger studies are needed to confirm the effects of I on survival in patients with coronary artery disease.